ArticleFrontiers in immunology2022

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).

Raju Sunagar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.